Compare LITB & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITB | INTS |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 24.0M |
| IPO Year | N/A | 2023 |
| Metric | LITB | INTS |
|---|---|---|
| Price | $2.06 | $0.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.33 |
| AVG Volume (30 Days) | 6.7K | ★ 3.2M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $219,105,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $0.19 |
| 52 Week High | $4.17 | $3.17 |
| Indicator | LITB | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 47.81 |
| Support Level | $1.73 | $0.40 |
| Resistance Level | $1.86 | $0.46 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 78.50 | 27.63 |
LightInTheBox Holding Co Ltd is an online retail company delivering products directly to consumers across the world. It provides apparel products including customized, special occasion and fast fashion apparel products; and other general merchandise products, such as accessories and gadgets, home and garden products, electronics and communication devices, and other products. The company operates in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of provision of logistic services to companies and to individual customers. It derives maximum revenue from Product Sales. Geographically, it operates in Europe which is the key revenue driver, North America, and other countries.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.